AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17659194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with CYP3A4-MET statins
Number of subjects: 15603
Study 17659194 — intervention group
Group type: COMPARATOR
Intervention: Placebo with CYP3A4-MET statins
Number of subjects: 15603
Study 17659194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with non-CYP3A4-MET statins
Number of subjects: 15603
Study 17659194 — intervention group
Group type: COMPARATOR
Intervention: Placebo with non-CYP3A4-MET statins
Number of subjects: 15603
Study 17659194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with atorvastatin
Number of subjects: 15603
Study 17659194 — intervention group
Group type: COMPARATOR
Intervention: Placebo with atorvastatin
Number of subjects: 15603
Study 17659194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with pravastatin
Number of subjects: 15603
Study 17659194 — intervention group
Group type: COMPARATOR
Intervention: Placebo with pravastatin
Number of subjects: 15603
Study 15821659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp scissors and hemoclips (Group 3)
Number of subjects: 90
Study 15821659 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery (Group 1)
Number of subjects: 90
Study 15821659 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scalpel (Group 2)
Number of subjects: 90
Study 12657846 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg intravenously every 12 h)
Number of subjects: 12
Study 12657846 — intervention group
Group type: COMPARATOR
Intervention: Troleandomycin (every 6 h)
Number of subjects: 12
Study 12657846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11140216 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Number of subjects: 0
Study 11140216 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8666704 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hypnotizable participants
Number of subjects: 2
Study 8666704 — intervention group
Group type: COMPARATOR
Intervention: Simulators (low-hypnotizable control participants)
Number of subjects: 2
Study 2064956 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (two doses on the first 2 days of induction)
Number of subjects: 829
Study 2064956 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without daunorubicin
Number of subjects: 829
Study 2064956 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment continued for 3 years
Number of subjects: 829
Study 2064956 — intervention group
Group type: COMPARATOR
Intervention: Treatment stopped after 2 years
Number of subjects: 829
Study 2064956 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (including all agents)
Number of subjects: 829
Study 6367371 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50-100 mg once daily
Number of subjects: 25
Study 6367371 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25-50 mg 3 times daily
Number of subjects: 25
Study 6367371 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril combined with hydrochlorothiazide (25-50 mg)
Number of subjects: 25
Study 6367371 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol combined with hydrochlorothiazide (25-50 mg)
Number of subjects: 25
Study 31778021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanser with 5‐aminolevulinic acid and peptides
Number of subjects: 60
Study 31778021 — intervention group
Group type: COMPARATOR
Intervention: Basic cleanser (control)
Number of subjects: 60
Study 30744621 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 243
Study 30744621 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus diet
Number of subjects: 243
Study 30744621 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study 30744621 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between diet and exercise plus diet
Number of subjects: 243
Study 28660421 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of space closure 2-4 weeks after tooth extraction (arm A)
Number of subjects: 74
Study 28660421 — intervention group
Group type: COMPARATOR
Intervention: Initiation of space closure ≥12 weeks after tooth extraction (arm B)
Number of subjects: 74
Study 28660421 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary sites
Number of subjects: 74
Study 28660421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular sites
Number of subjects: 74
Study 28660421 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of gingival invaginations
Number of subjects: 74
Study 25226307 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat Group (SG) - n = 10
Number of subjects: 21
Study 25226307 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-off Group (TG) - n = 11
Number of subjects: 21
Study 25226307 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 21
Study 24395497 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI) and bivalirudin infusion
Number of subjects: 0
Study 24395497 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI) and unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI)
Number of subjects: 0
Study 21465244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 14
Study 21465244 — intervention group
Group type: COMPARATOR
Intervention: Control (CC)
Number of subjects: 14
Study 18977464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 8
Study 18977464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17112460 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-containing gum
Number of subjects: 50
Study 17112460 — intervention group
Group type: COMPARATOR
Intervention: Control gum (without chitosan)
Number of subjects: 50
Study 15196153 — intervention group
Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex hydrogel formulation (0.025%)
Number of subjects: 66
Study 15196153 — intervention group
Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex in moisturizing base (0.025%)
Number of subjects: 66
Study 15196153 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel placebo base
Number of subjects: 66
Study 15196153 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer placebo base
Number of subjects: 66
Study 15196153 — intervention group
Group type: COMPARATOR
Intervention: Commercial RA product (0.05%)
Number of subjects: 66
Study 15196153 — intervention group
Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex in moisturizing base
Number of subjects: 66
Study 15196153 — intervention group
Group type: EXPERIMENTAL
Intervention: RA/beta‐CD complex hydrogel formulation
Number of subjects: 66
Study 15196153 — intervention group
Group type: EXPERIMENTAL
Intervention: RA/beta‐CD preparations
Number of subjects: 66
Study 11772826 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (12 mg)
Number of subjects: 18
Study 11772826 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (12 mg)
Number of subjects: 18
Study 11772826 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (4-12 mg)
Number of subjects: 18
Study 11772826 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (4-12 mg)
Number of subjects: 18
Study 10586386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (2 mg) with ketoconazole (200 mg) given 2 hours prior to probes
Number of subjects: 12
Study 10586386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (2 mg) with ketoconazole (200 mg) given simultaneously
Number of subjects: 12
Study 10586386 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin breath test (3 microCi)
Number of subjects: 12
Study 10586386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (2 mg)
Number of subjects: 12
Study 8933995 — intervention group
Group type: EXPERIMENTAL
Intervention: Alniditan 1.2 mg
Number of subjects: 171
Study 8933995 — intervention group
Group type: EXPERIMENTAL
Intervention: Alniditan 1.4 mg
Number of subjects: 171
Study 8933995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 1860148 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg mefloquine
Number of subjects: 20
Study 1860148 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 mg mefloquine
Number of subjects: 20
Study 6349649 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (300 mg/day)
Number of subjects: 417
Study 6349649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 27036157 — intervention group
Group type: EXPERIMENTAL
Intervention: Change-related SOC (self-efficacy)
Number of subjects: 225
Study 27036157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ending in change-related SOC
Number of subjects: 225
Study 29733110 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser at 5% density
Number of subjects: 15
Study 29733110 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser at 15% density
Number of subjects: 15
Study 29733110 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 5% density
Number of subjects: 15
Study 29733110 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 15% density
Number of subjects: 15
Study 29733110 — intervention group
Group type: COMPARATOR
Intervention: Unanesthetized reference
Number of subjects: 15
Study 27609756 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate combination antiretroviral therapy (cART)
Number of subjects: 53
Study 27609756 — intervention group
Group type: COMPARATOR
Intervention: Deferred cART
Number of subjects: 53
Study 27609756 — intervention group
Group type: COMPARATOR
Intervention: Immediate cART vs Deferred cART
Number of subjects: 53
Study 24439714 — intervention group
Group type: EXPERIMENTAL
Intervention: FLUSH test (agitated saline solution flush)
Number of subjects: 51
Study 23375921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-anchored treatment group
Number of subjects: 62
Study 23375921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored treatment group
Number of subjects: 62
Study 23375921 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 20646352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis and zinc suspension
Number of subjects: 122
Study 20646352 — intervention group
Group type: COMPARATOR
Intervention: Control (elimination of environmental risk factors only)
Number of subjects: 122
Study 18766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar floating ball (MFB)
Number of subjects: 76
Study 18766414 — intervention group
Group type: COMPARATOR
Intervention: Bipolar forceps (BF)
Number of subjects: 76
Study 16023821 — intervention group
Group type: EXPERIMENTAL
Intervention: GP desktop resource (GDR)
Number of subjects: 0
Study 16023821 — intervention group
Group type: COMPARATOR
Intervention: Concern about the doctor‐patient relationship
Number of subjects: 0
Study 12954743 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (16 mg) and Naloxone (4 mg)
Number of subjects: 326
Study 12954743 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine alone (16 mg)
Number of subjects: 326
Study 12954743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 10829350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (Exelon‐Novartis)
Number of subjects: 0
Study 10829350 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (Aricept‐Eisai; Pfizer)
Number of subjects: 0
Study 8874905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 272
Study 8874905 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 272
Study 1577043 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release paracetamol 500 mg
Number of subjects: 10
Study 1577043 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release paracetamol 1000 mg
Number of subjects: 10
Study 1577043 — intervention group
Group type: COMPARATOR
Intervention: Sustained release paracetamol 2000 mg
Number of subjects: 10
Study 1577043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3001149 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 6 g/d for 6 d
Number of subjects: 0
Study 3001149 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DCHA) 6 g/d for 6 d
Number of subjects: 0
Study 31394993 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Number of subjects: 1718
Study 31394993 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Number of subjects: 1718
Study 31394993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1718
Study 28846541 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 Fr SheathLess hydrophilic‐coated guide catheter (SH‐GC)
Number of subjects: 600
Study 28846541 — intervention group
Group type: COMPARATOR
Intervention: 6.0 Fr Glidesheath Slender (GSS)
Number of subjects: 600
Study 27304603 — intervention group
Group type: EXPERIMENTAL
Intervention: POD FineVision IOL
Number of subjects: 21
Study 27304603 — intervention group
Group type: EXPERIMENTAL
Intervention: FineVision/MicroF IOL
Number of subjects: 21
Study 25491243 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexed stories
Number of subjects: 103
Study 25491243 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected stories
Number of subjects: 103
Study 25491243 — intervention group
Group type: EXPERIMENTAL
Intervention: Text or animated conversational agent
Number of subjects: 103
Study 22772859 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O
Number of subjects: 52
Study 22772859 — intervention group
Group type: COMPARATOR
Intervention: ZEEP (PEEP 0 H2O)
Number of subjects: 52
Study 20428872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospira filgrastim (10 microg/kg, i.v.)
Number of subjects: 48
Study 20428872 — intervention group
Group type: COMPARATOR
Intervention: Amgen filgrastim (10 microg/kg, i.v.)
Number of subjects: 48
Study 20428872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospira filgrastim (10 microg/kg, s.c.)
Number of subjects: 48
Study 20428872 — intervention group
Group type: COMPARATOR
Intervention: Amgen filgrastim (10 microg/kg, s.c.)
Number of subjects: 48
Study 18672110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE)
Number of subjects: 107
Study 18672110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 107
Study 18672110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU)
Number of subjects: 107
Study 18672110 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (EE, IBU, PL)
Number of subjects: 107
Study 15962651 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily for 30 weeks
Number of subjects: 42
Study 15962651 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 weeks
Number of subjects: 42
Study 12885681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 3564
Study 12885681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3564
Study 10190398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 496
Study 10190398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 8754377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin, antibiotic, Metronidazole, and prostaglandins
Number of subjects: 143
Study 8754377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 143
Study 8261257 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol reduction
Number of subjects: 0
Study 2956865 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg enoximone
Number of subjects: 60
Study 2956865 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg enoximone
Number of subjects: 60
Study 2956865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoximone
Number of subjects: 60
Study 2956865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg enoximone
Number of subjects: 60
Study 2956865 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg enoximone
Number of subjects: 60
Study 31403552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pulsatile Machine Perfusion (MP)
Number of subjects: 51
Study 31403552 — intervention group
Group type: COMPARATOR
Intervention: Static Cold Storage (CS)
Number of subjects: 51
Study 29562983 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for at least 6 months
Number of subjects: 974
Study 29562983 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 974
Study 27334562 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS response scale version
Number of subjects: 446
Study 27334562 — intervention group
Group type: COMPARATOR
Intervention: Likert-type response scale version
Number of subjects: 446
Study 27164919 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol diet (6 portions of fruit and vegetables including 1 portion of berries/day and 50g of dark chocolate)
Number of subjects: 92
Study 27164919 — intervention group
Group type: COMPARATOR
Intervention: Low-polyphenol diet (continued for 8 weeks)
Number of subjects: 92
Study 27164919 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol diet
Number of subjects: 92
Study 23649508 — intervention group
Group type: EXPERIMENTAL
Intervention: UPPP + Repose
Number of subjects: 78
Study 23649508 — intervention group
Group type: COMPARATOR
Intervention: UPPP alone
Number of subjects: 78
Study 21859733 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation tyrosine kinase inhibitors (nilotinib or dasatinib)
Number of subjects: 350
Study 21859733 — intervention group
Group type: COMPARATOR
Intervention: Interferon-α therapy (control group)
Number of subjects: 350
Study 19758824 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet (35% soy protein, 35% animal protein, 30% other vegetable proteins)
Number of subjects: 14
Study 19758824 — intervention group
Group type: COMPARATOR
Intervention: Animal protein diet (70% animal and 30% vegetable proteins)
Number of subjects: 14
Study 17074639 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7009 (3‐hour intravenous infusion)
Number of subjects: 122
Study 17074639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 17074639 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7009
Number of subjects: 122
Study 15658649 — intervention group
Group type: EXPERIMENTAL
Intervention: Quchi needling (Group B)
Number of subjects: 60
Study 15658649 — intervention group
Group type: COMPARATOR
Intervention: Captopril (Control Group C)
Number of subjects: 60
Study 15658649 — intervention group
Group type: EXPERIMENTAL
Intervention: Taichong needling (Group A)
Number of subjects: 60
Study 11708589 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program intervention (10 half-hour sessions over 2 weeks)
Number of subjects: 22
Study 11708589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 9950305 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (50 mg/kg per day for 6 weeks followed by 50 mg/kg per day twice weekly for 6 weeks)
Number of subjects: 102
Study 9950305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 7522017 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dose)
Number of subjects: 20
Study 7522017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2783023 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 252
Study 2783023 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 252
Study 1090174 — intervention group
Group type: EXPERIMENTAL
Intervention: Deladumone OB
Number of subjects: 235
Study 1090174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 31977668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberosity-Based Plate (TBP)
Number of subjects: 10
Study 31977668 — intervention group
Group type: COMPARATOR
Intervention: Standard Proximal Humeral Locking Plate (PHLP)
Number of subjects: 10
Study 31719010 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated suture
Number of subjects: 508
Study 31719010 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-antibiotic suture
Number of subjects: 508
Study 28802565 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided pancreatic cyst lavage with normal saline (alcohol-free group)
Number of subjects: 39
Study 28802565 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided pancreatic cyst lavage with 80% ethanol (control group)
Number of subjects: 39
Study 25335249 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming‐promotion acupuncture
Number of subjects: 90
Study 25335249 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 90
Study 25335249 — intervention group
Group type: COMPARATOR
Intervention: Care group (psychological treatment)
Number of subjects: 90
Study 24330450 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical technique
Number of subjects: 150
Study 24330450 — intervention group
Group type: COMPARATOR
Intervention: Alternative technique with coverage of the pancreatic remnant by the falciform ligament
Number of subjects: 150
Study 20855064 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC (magnetic maneuverable capsule)
Number of subjects: 10
Study 20855064 — intervention group
Group type: COMPARATOR
Intervention: ESO2 (conventional capsule)
Number of subjects: 10
Study 25159907 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 136
Study 17221169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg) b.i.d for 3 months plus scaling and root planing (SRP)
Number of subjects: 65
Study 17221169 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules b.i.d for 3 months plus scaling and root planing (SRP)
Number of subjects: 65
Study 12926129 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + RT (three courses of chemotherapy followed by radiotherapy)
Number of subjects: 61
Study 12926129 — intervention group
Group type: COMPARATOR
Intervention: RT (radiotherapy alone)
Number of subjects: 61